WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

For decades, the US healthcare system has struggled to address the diet-related chronic illnesses affecting nearly half of ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...